Lupin Limited, an innovation-led transnational pharmaceutical company, Q3 FY23 revenue was up 3.9% to Rs. 4,322 crore whereas profit after tax was down 71% at Rs. 157.6 crore. 

 

Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, “We continued to build on our momentum in the quarter with growth in sales and improvement in profitability. Sales in the US have improved on the back of new product launches and the brand acquisition we made during the quarter. Excluding the impact of genericization on our diabetes portfolio, the India business has performed in line with the market. With the recent sales force expansion and new product launches, we expect to be back to above-market growth. We are committed to executing on our strategic initiatives to drive long-term growth and profitability, and maintaining the highest standards of quality and compliance.”

 

Investment in R&D was Rs. 289.6 crore (6.8% of sales) for Q3 FY2023, compared to Rs. 354.6 crore (8.7% of sales) for Q3 FY2022.

Lupin received approval for 2 ANDAs from the USFDA in the quarter. Cumulative ANDA filings with the USFDA stand at 469 as of December 31, 2022, with the company having received 302 approvals to date.

 

The company now has 55 First-to-File (FTF) filings including 21 exclusive FTF opportunities. Cumulative US DMF filings stand at 171 as of Dec 31, 2022.

 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

 

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the US by prescription. The company invested 8.7% of its revenue in research and development in FY22.

 

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally.